XTL Biopharmaceuticals Ltd (TA:XTLB) — Market Cap & Net Worth
Market Cap & Net Worth: XTL Biopharmaceuticals Ltd (XTLB)
XTL Biopharmaceuticals Ltd (TA:XTLB) has a market capitalization of $4.25 Million (ILA1.59 Billion) as of September 17, 2026. Listed on the TA stock exchange, this Israel-based company holds position #28992 globally and #419 in its home market, demonstrating a -5.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XTL Biopharmaceuticals Ltd's stock price ILA1.80 by its total outstanding shares 881385176 (881.39 Million). Also see XTL Biopharmaceuticals Ltd (XTLB) total assets for a full breakdown of the balance sheet.
XTL Biopharmaceuticals Ltd Market Cap History: 2015 to 2026
XTL Biopharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.32K to $4.25 Million (106.42% CAGR). Also see XTL Biopharmaceuticals Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
XTL Biopharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XTL Biopharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check XTL Biopharmaceuticals Ltd (XTLB) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
34.58x
XTL Biopharmaceuticals Ltd's market cap is 34.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $15.60 Million | $451.00K | -$1.03 Million | 34.58x | N/A |
Competitor Companies of XTLB by Market Capitalization
Companies near XTL Biopharmaceuticals Ltd in the global market cap rankings as of September 17, 2026. Review tangible equity quality of XTL Biopharmaceuticals Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to XTL Biopharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
XTL Biopharmaceuticals Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, XTL Biopharmaceuticals Ltd's market cap moved from $1.32K to $ 4.25 Million, with a yearly change of 106.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA4.25 Million | -25.00% |
| 2025 | ILA5.67 Million | -63.64% |
| 2024 | ILA15.60 Million | +88.57% |
| 2023 | ILA8.27 Million | -18.60% |
| 2022 | ILA10.16 Million | -47.94% |
| 2021 | ILA19.52 Million | -12.24% |
| 2020 | ILA22.24 Million | +6285.41% |
| 2019 | ILA348.30K | +121965.62% |
| 2018 | ILA285.34 | -22.89% |
| 2017 | ILA370.05 | -28.45% |
| 2016 | ILA517.18 | -60.68% |
| 2015 | ILA1.32K | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of XTL Biopharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.25 Million USD |
| MoneyControl | $4.25 Million USD |
| MarketWatch | $4.25 Million USD |
| marketcap.company | $4.25 Million USD |
| Reuters | $4.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more